Health Care • Biotechnology: Pharmaceutical Preparations
$9.66 ▼ -0.17
(-1.78%)
MKT CAP: $1.17B • VOL: 1.94M
52W L $3 52W H $11
VSTM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $30.9M | $10.0M | $0 |
| YoY Revenue Growth % | +209.1% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$170.1M | -$115.0M | -$92.1M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$209.5M | -$130.6M | -$87.4M |
| EBITDA (Normalized) | — | -$114.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$137.5M | -$104.8M | -$86.5M |
| Capital Expenditures (CapEx) | — | $28.0K | — |
| Free Cash Flow (FCF) | -$137.5M | -$104.8M | -$86.5M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $205.0M | $88.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $57.2M | -$28.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VSTM.